Metrics as of 10/17/2026, 08:29 AM (Berlin time), refresh in progress.
InflaRx Stock
InflaRx N.V.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- CEO
- Niels C. Riedemann
- Employees
- 65
- Market cap
- $195 M
- IPO
- 07/11/2017
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology. The company primarily operates in Germany and the United States. Its focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
InflaRx stock: price history
1D
-8.3%
1W
-17.5%
1M
-35.3%
6M
-17.0%
YTD
+30.7%
1Y
+6.5%
2Y
-12.6%
5Y
-46.6%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~28% weaker price swings than usual
Ask the agents about InflaRx
Analyst assessment of InflaRx
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
1
STRONG BUY
12
BUY
2
HOLD
1
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 07/08/2026
InflaRx stock metrics
P/E
-2.4
P/B
0.95
EV/EBITDA
-0.71
RETURN ON EQUITY
-7.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.2%
FLOAT SHARES
125,614,567
AVG. DAILY VOLUME (30D)
562,038
Institutional holders
Comparable stocks
Frequently asked questions about InflaRx stock
What does InflaRx do?
InflaRx N.V. is a company in the Healthcare sector, Biotechnology industry, headquartered in Germany.
The CEO is Niels C. Riedemann, the company employs around 65 people.
The IPO was on 07/11/2017; the stock trades on NASDAQ under the ticker IFRX.
What do analysts say about InflaRx stock?
16 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does InflaRx report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -28% stronger than usual.
Does InflaRx pay a dividend?
No, InflaRx currently does not pay a dividend.
Which stocks are comparable to InflaRx?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get InflaRx stock analyzed?
Clicking "Analyze stock" lets five strategies assess InflaRx against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.